Business Wire

Empatica Announces Plans for Landmark Clinical Study to Develop an AI-Based Seizure Forecast Based on Wearable Real-World Data

Share

Empatica, a digital health and AI company developing medical-grade wearables and digital biomarkers for health monitoring and diagnostics, today announced plans to launch a first-of-its-kind study aimed at developing a seizure forecasting algorithm for people living with epilepsy, based on real-world data collected using its technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231130692933/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Empatica announces plans to develop an AI-based seizure forecasting algorithm based on wearable real-world Data (Graphic: Business Wire)

More than 3 million Americans suffer from epilepsy, according to numbers from the Centers for Disease Control. And around one third of people with epilepsy have refractory epilepsy which occurs when medications no longer control seizures1. Epileptic seizures are disruptive health events that can have a significant negative impact on quality of life and increase risk of injury and death for people with epilepsy. This study is designed to identify individualized periods of seizure risk for patients with epilepsy, using biomarker viability and patterns in patient lifestyle data as inputs to a forecasting algorithm.

“Seizure forecasting has long been among the most-requested features for people with epilepsy. We are excited to announce our plans to begin a large clinical study aimed at using wearable technology to enable reliable seizure forecasting,” said Dr. Rosalind Picard, Co-Founder and Chief Scientist at Empatica. “Patients with epilepsy understand the toll that uncertainty around seizures takes and we hope that this study will help give them better control over their life, reducing stress and perhaps also enabling early interventions that ultimately reduce or prevent seizures from happening.”

This study builds on Empatica’s proven experience in monitoring neurological conditions like epilepsy. Empatica’s Embrace smartwatch is the first and only FDA-cleared wearable technology for detecting possible convulsive seizures, and one of the first AI-enabled medical products cleared by the FDA. Empatica’s wearables have also been previously used to successfully collect data shown to forecast seizures in a peer-reviewed study by the Mayo Clinic, King’s College and University of Melbourne, funded by the Epilepsy Foundation through the Seizure Gauge initiative2. Through the upcoming study, Empatica plans to use its expertise in AI and machine learning, as well as its access to the largest real-world dataset of convulsive seizures, for the development of the seizure forecasting algorithm.

This study also furthers Empatica’s work in developing AI-powered predictive algorithms. In 2021, Empatica developed an AI-based predictive algorithm which was CE-marked for medical use in the EU, focused on providing a warning when early signs of respiratory infections, including Covid-19, are detected.

Recruitment for the study will begin in early 2024. Individuals who are interested in being contacted for study participation when recruitment begins can visit empatica.com/seizure-forecasting to learn more.

About Empatica
Empatica Inc is a pioneer in continuous, unobtrusive remote health monitoring driven by AI. Empatica's platform and technology are used by thousands of institutional partners for research purposes, in studies examining stress, sleep, epilepsy, migraine, depression, addiction, and other conditions. Its flagship medical wearable, EmbracePlus, has been developed with key partners including HHS, USAMRDC, and the NASA-funded TRISH. Empatica’s award-winning Embrace watch is the world’s first and only FDA-cleared smart watch in neurology, for its ability to detect epileptic seizures.

__________________________
1https://www.cdc.gov/epilepsy/data/index.html
2https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578354/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media inquiries:
Aulani Capuchin
Real Chemistry (On Behalf of Empatica)
acapuchin@realchemistry.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Opengear Launches Enhanced Technical Certification Program22.2.2024 07:00:00 CET | Press release

Opengear, a Digi International company (NASDAQ, DGII, www.digi.com) and provider of secure and Smart Out of Band management solutions, today announced the launch of its enhanced Technical Certification Program, aimed at empowering IT professionals and network engineers in the Opengear network of channel and distribution organizations with comprehensive technical expertise to address evolving network challenges on the First Day, Worst Day, and Every Day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240221739136/en/ Opengear launches its enhanced Technical Certification Program, providing technical professionals with the knowledge and expertise required to effectively navigate and manage complex network infrastructures. (Graphic: Business Wire) Developed by Opengear's channel engineers, the Technical Certification Program is a robust e-learning initiative designed specifically to equip solution architects and sales engineers

Lenovo Group: Third Quarter Results 2023/2422.2.2024 05:26:00 CET | Press release

Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today announced third quarter results reporting Group revenue increasing 3% year-on-year to US$15.7 billion, and Group profitability improving quarter-to-quarter for the second time in a row. Net income was US$357 million on a non-Hong Kong Financial Reporting Standards (non-HKFRS)[1] basis, with net income margin up 0.4% quarter-to-quarter to 2.3%. The Group’s diversified growth engines continued to deliver strong performance, with revenue from non-PC businesses accounting for 42% of Group revenue, up 1.3 points year-on-year. The consistent quarter-to-quarter improvements over past quarters have been driven by the resilience of the Group’s core businesses and the wider effectiveness of its ongoing transformation. The SSG business hit an important milestone of passing the US$2 billion revenue threshold, achieved a record high operating profit with operating margin of over 20% and grew revenue fr

BlueConic Named the Only Challenger in Inaugural 2024 Gartner® Magic Quadrant™ for Customer Data Platforms21.2.2024 18:33:00 CET | Press release

Market-leading customer data platform (CDP) BlueConic today announced that it has been recognized as the only Challenger in the inaugural Magic Quadrant for Customer Data Platforms. We believe this industry recognition marks a major milestone for CDPs and the maturity of the space on a global scale. BlueConic differentiates from other vendors for its: Privacy-by-design philosophy: Maintaining responsible data practices is essential for garnering consumer trust, but maintaining compliance with a patchwork of regulations is only getting more difficult. That’s why BlueConic has been built with privacy at the forefront. The platform has been purposely designed to collect first-party data in ways that ensures it is unified, actionable, and privacy-compliant. Collecting and using data within the framework of privacy regulations like GDPR and CCPA enables companies to build trust and deliver valuable customer experiences, while mitigating their consumer data risk at the same time. Easy-to-use

Bynder named a “Leader” in Digital Asset Management by independent research firm21.2.2024 17:58:00 CET | Press release

Bynder, the global, enterprise digital asset management (DAM) platform, has been named a “Leader” in The Forrester Wave™: Digital Asset Management Systems, Q1 2024 report by Forrester Research, Inc. Bynder received a top score in the revenue category, with the report stating that “Bynder invests to play a transformative role in the digital-first economy.” In the past two years since the last report was launched, Bynder has surpassed $130m in ARR, announced a majority investment from Thomas H. Lee Partners, made two acquisitions, developed its enterprise partner ecosystem, launched more than 45 out of the box integrations and expanded its suite of product offerings to include AI capabilities and other new innovations that are redefining DAM. According to a quote from a customer reference in the report “the AI search and smart filter system in Bynder simplifies the process of finding the exact assets you’re looking for.” These recent AI innovations have highlighted the company’s market l

Parse Biosciences Launches Evercode Whole Transcriptome Version 3, Boosting Usability and Performance21.2.2024 17:00:00 CET | Press release

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced a significant update to the company’s flagship Evercode™ Whole Transcriptome products. Available to ship in mid-March, Evercode Whole Transcriptome version 3 kits offer researchers a more streamlined workflow, more flexible and higher throughput fixation, and optimized reagents for improved sensitivity in gene detection. With the new version, customers will enjoy a more streamlined and flexible workflow, helping them move from samples to results more quickly. These enhancements are delivered while significantly improving upon the previous version’s sensitivity and library complexity, giving researchers higher biological resolution and insight into their samples. Parse customers already rely on the utility of Evercode fixation, which enables them to fix cells or nuclei when they become available, store them for up to six months, and then sequence them when ready. Fixation i

HiddenA line styled icon from Orion Icon Library.Eye